AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has announced a new clinical study titled ‘A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA).’ The study aims to evaluate the safety and immune response of two investigational vaccines, AZD4117 and AZD5315, designed to protect against avian Influenza A (H5N1 and H7N9 subtypes). This research is significant as it addresses the need for effective vaccines against these potentially pandemic strains.
The study will test two vaccines, AZD4117 and AZD5315, both administered via intramuscular injection. These biological interventions are intended to stimulate an immune response to prevent influenza.
The study design is interventional, with a randomized allocation and a sequential intervention model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose is prevention.
The study is set to begin on August 5, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on August 28, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study could have significant market implications for AstraZeneca, potentially boosting its stock performance if successful results are announced. The involvement of collaborators like the Biomedical Advanced Research and Development Authority highlights the importance of this research in the broader pharmaceutical and biotech industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.